<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00497601</url>
  </required_header>
  <id_info>
    <org_study_id>BSV-AMBE II-KA-706</org_study_id>
    <nct_id>NCT00497601</nct_id>
  </id_info>
  <brief_title>A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar</brief_title>
  <official_title>A Prospective, Single Center, Open-Label, Dose-Escalation Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Treatment Na√Øve Or Resistant Cases Of Visceral Leishmaniasis (Kala-Azar).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banaras Hindu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Banaras Hindu University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

        1. To evaluate the Safety and Efficacy of four different short-course regimens of
           Amphotericin B emulsion in treatment of Kala-azar (visceral leishmaniasis) subjects who
           are either treatment naive or treatment resistant to other antileishmanial drugs except
           amphotericin B containing preparations.

        2. To assess the safety and efficacy of single-bolus infusion of Amphotericin B emulsion in
           treatment of Kala-azar.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To evaluate the Safety and Efficacy of four different short-course regimens of
           Amphotericin B emulsion in treatment of Kala-azar (visceral leishmaniasis) subjects who
           are either treatment naive or treatment resistant to other antileishmanial drugs except
           amphotericin B containing preparations.

        2. To assess the safety and efficacy of single-bolus infusion of Amphotericin B emulsion in
           treatment of Kala-azar.

      Subjects will be administered the study drug in either of the following four dose levels in
      an ascending manner, starting with the first dosage regimen:

        -  7.5 mg/kg on day 1 and day3 (Regimen 1)

        -  10 mg/kg on day 1, followed by 5 mg/kg on day 3 (Regimen 2)

        -  12.5 mg/kg on day 1, followed by 2.5 mg/kg on day 3 (Regimen 3)

        -  Single-bolus infusion of 15 mg/kg over 2-4 hours on day 1 (Regimen 4)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and parasitological cure at end of treatment and final cure (no relapse) at six months, no hematological, hepatic or renal toxicity</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Visceral Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 and 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amphotericin B in fat emulsion (Amphomul) 10 mg/kg on day 1 and 5 mg/kg on day 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amphotericin B in fat emulsion (Amphomul) 12.5 mg/kg on day 1 and 2.5 mg/kg on day 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amphotericin B in fat emulsion (Amphomul) 15 mg/kg in a single dose administration on day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amphotericin B fat emulsion in visceral leishmaniasis</intervention_name>
    <description>Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 &amp; 3 in group A Amphotericin B in fat emulsion (Amphomul) 10 &amp; 5 mg/kg on day 1 &amp; 3 in group B Amphotericin B in fat emulsion (Amphomul) 12.5 &amp; 2.5 mg/kg on day 1 &amp; 3 in group C Amphotericin B in fat emulsion (Amphomul) 15 mg/kg on day 1 in group D</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <other_name>Amphomul</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amphotericin B fat emulsion</intervention_name>
    <description>Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <other_name>Amphomul</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amphotericin B in fat emulsion</intervention_name>
    <description>Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <other_name>Amphomul</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects between 18 years and 65 years of age (both inclusive).

          2. Subject/subject's legally acceptable representative is willing and able to give
             written informed consent to participate in the study.

          3. Treatment naive subjects having symptoms and/or signs of visceral leishmaniasis with
             parasitological confirmation of Kala-azar (by splenic or bone marrow aspirate smear
             examination).

        If subjects are previously treated with other antileishmanial drugs except amphotericin B
        containing preparations, they will be enrolled in the study only after clinical and
        parasitological evidence that the disease is unresponsive to adequate treatment with other
        drugs, and after an appropriate wash out period

        Exclusion Criteria:

          1. Subjects with past history of treatment with Amphotericin B for Kala-azar.

          2. Subjects positive for HIV infection.

          3. Concomitant life threatening or serious disease.

          4. Concurrent malaria (malarial parasite test to be negative prior to study treatment
             administration), tuberculosis or bacterial pneumonia.

          5. Haemoglobin &lt; 6 gm/dl, total leukocyte count &lt; 1,500/cmm, platelet count &lt; 50,000/cmm

          6. Abnormal liver and renal functions (BUN and serum creatinine &gt; 1.5 times upper limit
             of normal (ULN), AST/ALT &gt; 2.5 times ULN, and bilirubin &gt; 1.5 times ULN).

          7. Pregnant or nursing women.

          8. Known hypersensitivity to Amphotericin B or inactive ingredients of study drug
             formulation.

          9. Subjects receiving any of the medications prohibited by the study protocol.

         10. Evidence of significant haematological, cardiac, hepatic, renal, respiratory,
             neurological or metabolic disease or any condition which, in the opinion of the
             investigator, might interfere with the evaluation of the study objectives.

         11. Simultaneous participation in another trial or received any investigational product &lt;
             30 days prior to enrolment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shyam Sundar</last_name>
    <role>Principal Investigator</role>
    <affiliation>Banaras Hindu University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kala-azar Medical Research Center</name>
      <address>
        <city>Muzaffarpur</city>
        <state>Bihar</state>
        <zip>842001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2007</study_first_submitted>
  <study_first_submitted_qc>July 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2007</study_first_posted>
  <last_update_submitted>September 11, 2008</last_update_submitted>
  <last_update_submitted_qc>September 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2008</last_update_posted>
  <keyword>Visceral Leishmaniasis</keyword>
  <keyword>Amphotericin B</keyword>
  <keyword>Fat emulsion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Visceral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

